Review shows little to no difference in weight loss, quality of life compared with regular dietary advice or no intervention, waiting list
WEDNESDAY, Feb. 18, 2026 (HealthDay News) — Intermittent fasting seems to yield little to no difference in weight loss or quality of life for adults with overweight or obesity, according to a review published online Feb. 16 in the Cochrane Database.
Luis I. Garegnani, Ph.D., from the Universidad Hospital Italiano de Buenos Aires in Argentina, and colleagues conducted a systematic review to examine the benefits and harms of intermittent fasting versus regular dietary advice, no intervention, or waiting list for adults with overweight or obesity.
Twenty-two studies were included, with 1,995 participants. The researchers found that intermittent fasting may result in little to no difference in percentage from baseline weight loss compared with regular dietary advice. The evidence was very uncertain, but intermittent fasting may have little to no effect on achieving a 5 percent reduction in body weight, little to no difference in quality of life, and little to no effect on adverse events. Compared with no intervention or waiting list, intermittent fasting was likely to yield little to no difference in percentage weight loss from baseline, in quality of life, and in adverse events.
“With the current evidence available, it’s hard to make a general recommendation,” senior author Eva Madrid, from the Cochrane Evidence Synthesis Unit Iberoamerica, said in a statement. “Doctors will need to take a case-by-case approach when advising an overweight adult on losing weight.”
Abstract/Full Text (subscription or payment may be required)
Weight Regain Seen After Cessation of GLP-1 Receptor Agonists in Adults With Overweight, Obesity
Excess Prepregnancy Parental Adiposity Linked to Offspring MASLD
CDC Reports on Prevalence of Obesity, Severe Obesity in U.S. Adults, Children
Satisfaction With Semaglutide Driven by Effective Weight Loss
Health Consequences Vary by Chemo Regimen in Testicular Cancer Survivors
Meta-Analysis Identifies Few Adverse Events Attributed to Statin Use
Oxybutynin Beats Placebo for Reducing ADT-Linked Hot Flashes in Prostate Cancer
Sodium-Glucose Cotransporter 2 Inhibitors Tied to Lower Use of Gout Medications